Modulation of this pathway can be monitored through measurement of fasting serum insulin, IGF-1, and IGFBP-3 levels, as well as by evaluating insulin resistance indices, such as the homeostatic model assessment for insulin resistance (HOMA-IR). This evidence concerns the gene IGFBP3 and Insulin resistance.